Rhythm Biosciences Limited (ASX:RHY)

Market Cap	28.31M +3.3%
Revenue (ttm)	1.74M -47.7%
Net Income	-5.93M
EPS	-0.02
Shares Out	353.87M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,670
Open	0.0810
Previous Close	0.0800
Day's Range	0.0800 - 0.0820
52-Week Range	0.0750 - 0.2800
Beta	0.43
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 3, 2026

About Rhythm Biosciences

Rhythm Biosciences Limited, a medical diagnostics company, develops and commercialises medical diagnostic tests for cancer detection in Australia and the United States. The company offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. Rhythm Biosciences Limited was incorporated in 2017 and is headquartered in Parkville, Australia.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2017
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RHY

Financial Performance

In fiscal year 2026, Rhythm Biosciences's revenue was 1.74 million, a decrease of -47.67% compared to the previous year's 3.33 million. Losses were -5.93 million, 54.9% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 17, 2026

Data Sources Report a data error